文献速递浆细胞疾病

EGFL7-ITGB3-KLF2轴增强多发性骨髓瘤临床前模型的生存

The EGFL7-ITGB3-KLF2 axis enhances survival of multiple myeloma in preclinical models.
PubMed 文献 · Blood Adv · 2020-01-01

本研究探讨血管分泌因子EGFL7在多发性骨髓瘤中的作用。恶性浆细胞表达EGFL7并表达其受体ITGB3,形成EGFL7-ITGB3-KLF2正反馈环路促进骨髓瘤细胞存活与增殖。阻断EGFL7信号可抑制骨髓瘤生长,并与硼替佐米协同。

要点

  • 骨髓瘤细胞表达EGFL7及其受体ITGB3,激活黏附与增殖信号。
  • EGFL7-ITGB3-KLF2正反馈环路维持骨髓瘤细胞存活。
  • 中和EGFL7抗体与硼替佐米协同抑制骨髓瘤细胞生长。

核心结论

  • EGFL7-ITGB3-KLF2轴促进多发性骨髓瘤细胞存活与增殖,靶向该轴可能成为治疗策略。

研究设计与样本

  • 临床前研究:使用多发性骨髓瘤细胞系、患者来源骨髓瘤细胞及NOD.CB17-Prkdcscid/J小鼠移植模型。

主要发现

  • 骨髓瘤细胞产生EGFL7并表达功能性受体ITGB3,导致ITGB3磷酸化及黏着斑激酶活化。
  • 过表达ITGB3或EGFL7增强骨髓瘤细胞黏附与增殖。
  • ITGB3过表达上调转录因子KLF2,KLF2进一步增强EGFL7转录,形成EGFL7-ITGB3-KLF2-EGFL7放大环路。
  • 在难治性骨髓瘤及初诊患者的部分浆细胞中检测到EGFL7表达。
  • 移植骨髓瘤细胞的NOD.CB17-Prkdcscid/J小鼠人血浆EGFL7水平升高。

临床怎么用

  • 抑制EGFL7信号可能与硼替佐米协同,作为抑制骨髓瘤细胞增殖的新策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Angiogenic factors play a key role in multiple myeloma (MM) growth, relapse, and drug resistance. Here we show that malignant plasma cells (cell lines and patient-derived MM cells) express angiocrine factor EGF like-7 (EGFL7) mRNA and protein. MM cells both produced EGFL7 and expressed the functional EGFL7 receptor integrin β 3 (ITGB3), resulting in ITGB3 phosphorylation and focal adhesion kinase activation. Overexpression of ITGB3 or EGFL7 enhanced MM cell adhesion and proliferation. Intriguingly, ITGB3 overexpression upregulated the transcription factor Krüppel-like factor 2 (KLF2), which further enhanced EGFL7 transcription in MM cells, thereby establishing an EGFL7-ITGB3-KLF2-EGFL7 amplification loop that supports MM cell survival and proliferation. EGFL7 expression was found in certain plasma cells of patients with refractory MM and of patients at primary diagnosis. NOD.CB17-Prkdc<scid>/J mice transplanted with MM cells showed elevated human plasma EGFL7 levels. EGFL7 knockdown in patient-derived MM cells and treatment with neutralizing antibodies against EGFL7 inhibited MM cell growth in vitro and in vivo. We demonstrate that the standard-of-care MM drug bortezomib upregulates EGFL7, ITGB3, and KLF2 expression in MM cells. Inhibition of EGFL7 signaling in synergy with BTZ may provide a novel strategy for inhibiting MM cell proliferation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Salama Y, Heida AH, Yokoyama K, et al. The EGFL7-ITGB3-KLF2 axis enhances survival of multiple myeloma in preclinical models. Blood Adv. 2020. PMID: 32191808. doi:10.1182/bloodadvances.2019001002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。